These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 3926306)

  • 1. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro.
    Keyes SR; Rockwell S; Sartorelli AC
    Cancer Res; 1985 Aug; 45(8):3642-5. PubMed ID: 3926306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells.
    Fracasso PM; Sartorelli AC
    Cancer Res; 1986 Aug; 46(8):3939-44. PubMed ID: 3089583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells.
    Keyes SR; Rockwell S; Sartorelli AC
    Cancer Res; 1989 Jun; 49(12):3310-3. PubMed ID: 2470504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells.
    Kennedy KA; Rockwell S; Sartorelli AC
    Cancer Res; 1980 Jul; 40(7):2356-60. PubMed ID: 7388797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical studies of porfiromycin as an adjunct to radiotherapy.
    Rockwell S; Keyes SR; Sartorelli AC
    Radiat Res; 1988 Oct; 116(1):100-13. PubMed ID: 3186923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between drug uptake and selective toxicity of porfiromycin to hypoxic EMT6 cells.
    Keyes SR; Rockwell S; Sartorelli AC
    Cancer Res; 1987 Nov; 47(21):5654-7. PubMed ID: 3664473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C.
    Keyes SR; Heimbrook DC; Fracasso PM; Rockwell S; Sligar SG; Sartorelli AC
    Adv Enzyme Regul; 1985; 23():291-307. PubMed ID: 3934922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the superoxide dismutase inhibitor, diethyldithiocarbamate, on the cytotoxicity of mitomycin antibiotics.
    Pritsos CA; Keyes SR; Sartorelli AC
    Cancer Biochem Biophys; 1989 Oct; 10(4):289-98. PubMed ID: 2559790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of the cytotoxicity of porfiromycin by dicoumarol in vitro and in vivo.
    Rockwell S; Keyes SR; Sartorelli AC
    Anticancer Res; 1989; 9(4):817-20. PubMed ID: 2479329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells.
    Marshall RS; Rauth AM
    Cancer Res; 1988 Oct; 48(20):5655-9. PubMed ID: 3167822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro.
    Keyes SR; Rockwell S; Sartorelli AC
    Cancer Res; 1985 Jan; 45(1):213-6. PubMed ID: 2578093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics.
    Pritsos CA; Sartorelli AC
    Cancer Res; 1986 Jul; 46(7):3528-32. PubMed ID: 3011250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential kill of hypoxic EMT6 mammary tumor cells by the bioreductive alkylating agent porfiromycin.
    Sartorelli AC; Belcourt MF; Hodnick WF; Keyes SR; Pritsos CA; Rockwell S
    Adv Enzyme Regul; 1995; 35():117-30. PubMed ID: 7572339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of deficiencies in DNA repair on the toxicity of mitomycin C and porfiromycin to CHO cells under aerobic and hypoxic conditions.
    Hughes CS; Irvin CG; Rockwell S
    Cancer Commun; 1991 Feb; 3(2):29-35. PubMed ID: 1899798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
    Donnelly ET; Kelley M; Rockwell S
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of mitomycin C alone and in combination with X-rays on EMT6 mouse mammary tumors in vivo.
    Rockwell S
    J Natl Cancer Inst; 1983 Oct; 71(4):765-71. PubMed ID: 6413743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions of BMS-181174 and radiation: studies with EMT6 cells in vitro and in solid tumors.
    Rockwell S; Kelley M
    Radiother Oncol; 1996 Apr; 39(1):65-71. PubMed ID: 8735495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck.
    Haffty BG; Son YH; Wilson LD; Papac R; Fischer D; Rockwell S; Sartorelli AC; Ross D; Sasaki CT; Fischer JJ
    Radiat Oncol Investig; 1997; 5(5):235-45. PubMed ID: 9372546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of a hypoxic cell selective cytotoxic agent (mitomycin C or porfiromycin) to Fluosol-DA/carbogen/radiation.
    Holden SA; Herman TS; Teicher BA
    Radiother Oncol; 1990 May; 18(1):59-70. PubMed ID: 2113698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1.
    Keyes SR; Fracasso PM; Heimbrook DC; Rockwell S; Sligar SG; Sartorelli AC
    Cancer Res; 1984 Dec; 44(12 Pt 1):5638-43. PubMed ID: 6437671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.